This site is intended for healthcare professionals

Enhertu continues to demonstrate durable responses with new data from DESTINY-Breast01 in HER2-positive metastatic breast cancer.- AstraZeneca + Daiichi Sankyo

Read time: 1 mins
Last updated:11th Dec 2020
Published:11th Dec 2020
Condition: Breast Cancer HER2+
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest